MannKind Corp
NASDAQ:MNKD
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.25
7.44
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MNKD stock under the Base Case scenario is 5.867 USD. Compared to the current market price of 7.275 USD, MannKind Corp is Overvalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
MannKind Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MNKD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
MannKind Corp
Balance Sheet Decomposition
MannKind Corp
Current Assets | 327.7m |
Cash & Short-Term Investments | 251.6m |
Receivables | 18.2m |
Other Current Assets | 57.9m |
Non-Current Assets | 136.5m |
Long-Term Investments | 16.8m |
PP&E | 99m |
Intangibles | 7.2m |
Other Non-Current Assets | 13.5m |
Current Liabilities | 72.1m |
Accounts Payable | 6.4m |
Accrued Liabilities | 19.8m |
Other Current Liabilities | 45.9m |
Non-Current Liabilities | 602m |
Long-Term Debt | 459.3m |
Other Non-Current Liabilities | 142.8m |
Earnings Waterfall
MannKind Corp
Revenue
|
267.2m
USD
|
Cost of Revenue
|
-75.1m
USD
|
Gross Profit
|
192.1m
USD
|
Operating Expenses
|
-134.9m
USD
|
Operating Income
|
57.3m
USD
|
Other Expenses
|
-35.7m
USD
|
Net Income
|
21.6m
USD
|
Free Cash Flow Analysis
MannKind Corp
USD | |
Free Cash Flow | USD |
MNKD Profitability Score
Profitability Due Diligence
MannKind Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
MannKind Corp's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
MNKD Solvency Score
Solvency Due Diligence
MannKind Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
MannKind Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MNKD Price Targets Summary
MannKind Corp
According to Wall Street analysts, the average 1-year price target for MNKD is 7.956 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for MNKD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MNKD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MannKind Corp. operates as a biopharmaceutical company. The company is headquartered in Danbury, Connecticut and currently employs 348 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.
Contact
IPO
Employees
Officers
The intrinsic value of one MNKD stock under the Base Case scenario is 5.867 USD.
Compared to the current market price of 7.275 USD, MannKind Corp is Overvalued by 19%.